About the Company
geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
26
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GOVX News
Geovax Labs Inc GOVX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call Transcript
GeoVax Labs, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome, everyone, to the GeoVax ...
GeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78
Geovax Labs Background Information (This description is provided by the company.) GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases ...
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE ...
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial ...
GeoVax to Present at the 36th Annual Roth Conference
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire-- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious ...
Earnings call: GeoVax outlines progress in clinical trials and financials
GeoVax Labs Inc. (NASDAQ:GOVX) provided updates on its clinical progress and financial status during their Fourth Quarter 2023 Corporate Update Call. CEO David Dodd outlined the company's ...
GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
Good afternoon, and welcome, everyone, to the GeoVax Fourth Quarter 2023 Corporate Update Call. My name is Desiree, and I will facilitate today's call. With me are David Dodd, Chairman and CEO ...
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious ...
GeoVax Labs Inc (GOVX)
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like ...
GeoVax, Inc.: GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world's most threatening infectious diseases.
Loading the latest forecasts...